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PCoronary Heart Disease
Lipoprotein-Associated Phospholipase A2 Is an
Independent Predictor of Incident Coronary Heart
Disease in an Apparently Healthy Older Population
The Rancho Bernardo Study
Lori B. Daniels, MD,* Gail A. Laughlin, PHD,† Mark J. Sarno, BA,‡ Ricki Bettencourt, MS,†
Robert L. Wolfert, PHD,‡ Elizabeth Barrett-Connor, MD†
San Diego, La Jolla, and South San Francisco, California
Objectives Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease (CHD) in adults
without known CHD, independent of heart disease risk factors. We examined whether the independent associa-
tion was apparent in older adults.
Background Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipids to yield potentially proatherogenic
particles, have been associated with CHD and may help predict cardiovascular risk.
Methods Participants were 1,077 community-dwelling men and women, median age 72 years, who had no known CHD at
baseline (1984 to 1987) when blood samples and risk factor data were collected. Participants were followed for
CHD events for a mean of 16 years, through 2002. Cox proportional hazards regression models were used to
examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina, or coronary revas-
cularization).
Results The Lp-PLA2 levels positively correlated with age (r  0.09), body mass index (r  0.11), low-density lipoprotein
(r  0.37), triglycerides (r  0.25), and C-reactive protein (r  0.10), and negatively correlated with high-density
lipoprotein (r  0.27) (all p  0.05). During follow-up, 228 participants had incident CHD events. Lipoprotein-
associated phospholipase A2 levels in the second, third, and fourth quartiles predicted an increased risk of CHD
compared with the lowest quartile (hazard ratios 1.66, 1.80, and 1.89, respectively; p  0.05 for each). This as-
sociation persisted after adjusting for C-reactive protein and other CHD risk factors.
Conclusions Elevated Lp-PLA2 levels predict CHD events in apparently healthy older adults, independent of CHD risk
factors. (J Am Coll Cardiol 2008;51:913–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.048a
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pipoprotein-associated phospholipase A2 (Lp-PLA2), also
nown as platelet-activating factor acetylhydrolase, is a 50-kd
alcium-independent enzyme synthesized by macrophages and
latelets (1). It is a member of the phospholipase A2 super-
amily, and is colocated with and highly expressed by macro-
hages within the necrotic core and the fibrotic cap of
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esearch grant AG07181 from the National Institute on Aging and grant DK31801
rom the National Institute of Diabetes and Digestive and Kidney Diseases. The
resent analysis was supported, in part, by a grant from the American Heart
ssociation (to Dr. Daniels). The Lp-PLA2 levels were measured by diaDexus, Inc.
r. Sarno and Ms. Bettencourt have received consulting fees from diaDexus, Inc. Dr.
olfert is employed by and owns stock options in diaDexus, Inc. Steven E. Nissen,
D, MACC, served as Guest Editor for this paper.f
Manuscript received June 27, 2007; revised manuscript received October 10, 2007,
ccepted October 11, 2007.dvanced rupture-prone plaques (2,3). The primary enzymatic
ole of Lp-PLA2 is to hydrolyze oxidized phospholipids,
ielding the proinflammatory and proatherogenic products,
ysophosphatidylcholine and oxidized nonesterified fatty acids.
hese bioactive products play critical roles in the induction of
hemotactic response, endothelial cell dysfunction, and smooth
uscle cell apoptosis (4). As such, Lp-PLA2 appears to be a
ey mediator of the proatherogenic process.
Several epidemiologic studies support the proatherogenic
ffects of Lp-PLA2, most of which have included only
iddle-aged men. Higher Lp-PLA2 levels were strongly
ssociated with an increased risk of incident coronary heart
isease (CHD) in a nested case-control analysis of 1,740
en with a mean age of 57 years from WOSCOPS (West
f Scotland Coronary Prevention Study) (5) and in a
rospective cohort analysis of 934 men ages 45 to 64 years
rom the MONICA (Monitoring Trends and Determinants
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(6). The significant elevation in
risk persisted in these studies af-
ter adjustment for traditional risk
factors and C-reactive protein
(CRP), a marker of systemic in-
flammation. A case-cohort anal-
ysis from the ARIC (Atheroscle-
rosis Risk In Communities)
study, which included both men
and women (n  1,652) ages 45
to 64 years, reported a strong
positive relationship between
Lp-PLA2 levels and CHD out-
comes. The association was inde-
pendent of traditional risk factors
nd CRP only in those with low-density lipoprotein (LDL)
holesterol 130 mg/dl (7). A nested case-control analysis
f 246 low-risk women from the Women’s Health study
mean age 60 years) also reported higher Lp-PLA2 levels in
omen with increased CHD risk, but adjustment for other
ardiovascular risk factors eliminated the association (8),
uggesting that Lp-PLA2 may not be as strong a predictor
f CHD in women.
Because age is the single most powerful predictor of heart
isease, it is possible that Lp-PLA2 levels do not contribute
nything further to CHD risk prediction in the elderly.
urrently, limited data are available on Lp-PLA2 mass
evels and incident CHD in the elderly. In the Rotterdam
tudy, where the mean age of subjects was 70 years and
edian follow-up was 7 years, those with higher baseline
evels of Lp-PLA2 activity were at increased risk for CHD
nd ischemic stroke, but data on LDL cholesterol levels or
p-PLA2 mass levels were not reported (9).
We investigated the ability of Lp-PLA2 to predict fatal
nd nonfatal CHD events independent of traditional risk
actors and CRP in community-dwelling older men and
omen who were in apparently good health and were
ollowed for an average of 16 years.
ethods
tudy population. The Rancho Bernardo study is an on-
oing population-based study of healthy aging in Caucasian
esidents of a Southern California community, which was
stablished in 1972. Between 1984 and 1987, 82% of surviving
ommunity-dwelling older participants attended a research
linic visit, which served as the baseline visit for the present
eport. The subjects of this report are the 1,077 participants age
40 years who at baseline had no history of cardiovascular
isease (myocardial infarction, coronary revascularization, an-
ina, stroke, or transient ischemic attack), who were not
urrent users of hormone therapy, and who had sufficient
rchived serum for measurement of Lp-PLA2. The study
Abbreviations
and Acronyms
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
CRP  C-reactive protein
HDL  high-density
lipoprotein
HR  hazard ratio
LDL  low-density
lipoprotein
Lp-PLA2  lipoprotein-
associated phospholipase A2rotocol was approved by the Institutional Review Board at the lniversity of California, San Diego; all participants provided
ritten, informed consent.
Medical history and incident CHD information were
btained using standardized questionnaires at baseline, at
linic visits approximately every 4 years thereafter, and from
eriodic mailings. Follow-up continued through 2002, an
8-year follow-up (mean follow-up 16 years). Study partic-
pants were classified as incident CHD cases if at any time
uring the follow-up period they had a fatal or nonfatal
yocardial infarction, coronary revascularization, or angina
grades 1 or 2 by Rose criteria) (10). Myocardial infarction
as diagnosed based on a history of physician-diagnosed
yocardial infarction or evidence of myocardial infarction
n resting 12-lead electrocardiogram using the Whitehall
riteria as applied in the World Health Organization’s
ultinational Study of Diabetes and Vascular Disease
Minnesota codes 1.1 to 1.2 [major Q-wave] or 7.1.1 [left
undle branch block]) (11,12). At another study visit,
iagnosis of a heart attack had been validated in 85% of the
ases by a panel of cardiologists who reviewed the medical
ecords of a 30% sample of this cohort.
Vital status was known for 96% of participants. Death
ertificates were obtained for 95% of all decedents and
oded by a certified nosologist using the International
lassification of Disease-9th Revision criteria; decedents
hose death certificates were unavailable were excluded
rom this analysis. Fatal CHD included deaths assigned
odes 410 through 414. Participants who were alive and
vent-free were censored at the end of follow-up (December
1, 2002), or at the date of their last follow-up for the 4%
hose status was unknown. Subjects who died of non-
HD causes were censored at time of death.
easurements. Baseline data for these analyses were ob-
ained in 1984 to 1987. Information on medical history,
edication use, physical activity (exercise 3 times per
eek, yes/no), alcohol consumption (1 drinks per day vs.
ess or none), and current smoking (yes/no) was obtained
sing standard questionnaires. Current medication use was
alidated by examination of pills and prescriptions brought
o the clinic for that purpose. Blood pressure was measured
y standard protocol as the mean of 2 readings after the
articipant had been sitting for 5 min. Body mass index
BMI) (kg/m2) was derived from height and weight mea-
ured in the clinic with participants wearing light clothing
nd no shoes.
Blood samples were obtained by venipuncture between
:30 AM and 11:00 AM after a requested 12-h fast. Serum
nd plasma were separated and stored at70°C. Lipids and
ipoproteins were measured on fresh samples in a Lipid
esearch Clinic laboratory at the University of California at
an Diego (San Diego, Calfornia). Total cholesterol and
riglyceride levels were measured by enzymatic techniques
sing an ABA-200 biochromatic analyzer (Abbott Labora-
ories, Irving, Texas). High-density lipoprotein (HDL)
holesterol was measured by precipitating other circulating
ipoproteins with heparin and manganese chloride accord-
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March 4, 2008:913–9 Lp-PLA2 Predicts Incident CHD in Older Adultsng to the standard Lipid Research Clinics protocol (13).
ow-density lipoprotein cholesterol was estimated using the
riedewald formula (14). Plasma glucose levels were mea-
ured by the glucose oxidase method. In 2000, plasma levels
f high-sensitivity CRP were measured in a university
ospital laboratory using an automated high-sensitivity
ssay (N Latex CRP mono, Dade Behring, Marburg,
ermany; sensitivity 0.2 mg/l) on previously unthawed
lasma that had been stored at 70°C.
Lipoprotein-associated phospholipase A2 mass levels
ere measured in 2005 using the PLAC test (diaDexus,
nc., South San Francisco, California) on frozen sera from
he same visit, which had been thawed 2 times previously.
he manufacturer reports that samples can be frozen and
hawed up to 6 times without affecting Lp-PLA2 quantifi-
ation. The assay is a microplate-based enzyme-linked
mmunoadsorbent assay, employing 2 monoclonal antibod-
es specific for Lp-PLA2, and calibrated to a recombinant
nzyme standard. The assay sensitivity was 1.3 ng/ml and
ntra- and interassay coefficients of variation were 6% and
9%, respectively.
Subjects were classified as persons with diabetes accord-
ng to 1999 World Health Organization criteria if the
asting plasma glucose was 126 mg/dl, the 2-h glucose
fter oral glucose tolerance test was 200 mg/dl, if they were
aking insulin or oral diabetes medication, or if they were
iagnosed as a patient with diabetes by a physician (15).
tatistical methods. Means are expressed  standard de-
iation. High-density lipoprotein, triglycerides, CRP, and
p-PLA2 were not normally distributed and were log
ransformed for analyses; geometric means are reported.
aseline characteristics were compared between cases and
oncases using general linear models adjusted for age for
ontinuous variables and chi-square analysis for categorical
ariables; categorical variables were adjusted using the ad-
usted proportions module in STATA, which calculates
djusted probabilities from logistic regression estimates
16). Associations between Lp-PLA2 and other risk factors
ere examined using Spearman rank-order correlation.
Multivariate Cox proportional hazards regression models
ere developed to determine the association of Lp-PLA2
ith incident CHD. The primary null hypothesis was that
p-PLA2 was not predictive of CHD events over and above
arious demographic variables and traditional risk factors.
esults were expressed as hazard ratios (HRs) with 95%
onfidence intervals (CIs). Study participants were catego-
ized into quartiles of Lp-PLA2, and 4 sequential Cox
egression models were generated. Model 1 adjusted for age
nd gender. For Model 2, life-style, risk factor, and labo-
atory covariates from Table 1 were analyzed, and univariate
redictors of CHD events were identified if significant at p
0.25. This process yielded age, gender, HDL, triglycer-
des, LDL, fasting plasma glucose, systolic blood pressure,
iabetes, hypertension, and Lp-PLA2 as potential predic-
ors. Cox regression analysis was performed using these 10 covariates (Model 2), and those that were significant at p 
.05 (age, gender, fasting plasma glucose, systolic blood
ressure, and Lp-PLA2) were retained in the final Model 3.
o 2-way interactions were identified. Model 4 incorpo-
ated the same covariates as Model 3 but included only the
ubset of participants who had CRP measurements available
n  815) so that the effect of adding CRP to the model
ould be distinguished from any effect due to loss of power.
odel 5 was the same as Model 4, but with CRP added as
covariate. All variables were treated as continuous variables
xcept gender, diabetes, history of hypertension, smoking
tatus, physical activity, and alcohol consumption, which
ere treated as dichotomous variables. The lowest quartile
as the reference group for all regressions.
Age-adjusted survival curves were generated by the average
ovariate method, computing a survival curve for each group
ith age set to the average value for the study sample (17).
eceiver-operating characteristic curves were constructed after
djustment for covariates, and the area under the curve with its
5% CI was calculated. Significance of differences between
eceiver-operating characteristic curves were tested using a
onparametric approach to the analysis of areas under corre-
ated curves (18). A 2-tailed p  0.05 was considered statisti-
ge-Adjusted Mean  SD or Prevalence ofisk Factors and Medicati ns at Baseline1984 to 1987)
Table 1
Age-Adjusted Mean  SD or Prevalence of
Risk Factors and Medications at Baseline
(1984 to 1987)
Variable
Cases
(n  228)
Noncases
(n  849)
p Value
(Cases Vs.
Noncases)
Age, yrs* 72.2 8.8 69.5 10.6 0.001
Women, %* 42.5 47.5 0.19
Lifestyle factors, %
Current smoker 12.2 12.2 0.97
Exercise 3/week 80.3 81.5 0.69
Alcohol daily 44.9 44.2 0.84
Medication use, %
Aspirin 17.2 18.6 0.65
Lipid-lowering drugs 0.4 0.5 0.88
Beta-blockers 14.3 12.2 0.41
Risk factors
Diabetes, % 15.9 12.2 0.13
Hypertension, % 67.0 60.6 0.093
BMI 25.6 3.6 25.0 3.6 0.041
Systolic BP, mm Hg 143 19 139 19 0.005
Diastolic BP, mm Hg 78 9 77 9 0.22
Laboratory values
Total cholesterol, mg/dl 223 40 218 40 0.078
HDL, mg/dl† 55 16 59 17 0.006
LDL, mg/dl 141 36 135 36 0.013
Triglycerides, mg/dl† 106 57 99 54 0.10
Fasting plasma glucose, g/dl 106 21 100 21 0.001
CRP, mg/l† 1.8 1.7 1.6 1.6 0.18
Lp-PLA2, ng/ml† 538 180 494 167 0.001
Unadjusted mean; all others are age-adjusted; †geometric mean.
BMI  body mass index; BP  blood pressure; CRP  C-reactive protein; HDL  high-density
ipoprotein; LDL  low-density lipoprotein; Lp-PLA2  lipoprotein-associated phospholipase A2;
D  standard deviation.ally significant. Data were analyzed using SAS, version 9.1
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Stata Corp., College Station, Texas).
esults
aseline characteristics. Of the 1,077 participants in the
tudy population, 228 (131 men, 97 women) experienced a
HD event during follow-up (mean 16 years) and were
ategorized as cases. The events included 86 (37.7%) fatal
yocardial infarction, 70 (30.7%) nonfatal myocardial in-
arction, 43 (18.9%) angina, and 29 (12.7%) revasculariza-
ion procedures, with mean time to event of 7.6 years.
oncases included 446 men and 403 women.
Baseline characteristics of the study population by CHD
tatus are shown in Table 1. In an analysis of baseline risk
actors and medication use, the study population was similar
o the overall cohort from which it was derived except that
hose without Lp-PLA2 measurements (n  494) were
lightly younger (69 vs. 70 years, p  0.01), more likely to
e women (59% vs. 46%, p  0.01), slightly more likely to
ave diabetes (17% vs. 13%, p  0.02), and had lower
iastolic blood pressure (76 mm Hg vs. 78 mm Hg, p 
.001).
As shown in Table 1, at baseline individuals who later
xperienced CHD events were significantly older (mean age
2.2 8.8 years vs. 69.5 10.6 years) and had significantly
igher BMI, systolic blood pressure, LDL, and Lp-PLA2
538 ng/ml vs. 494 ng/ml, p  0.001) and significantly
ower HDL levels than noncases. No significant differences
y CHD status were observed for CRP, diastolic blood
ressure, total cholesterol, triglycerides, or interleukin 6, nor
ere there differences in gender distribution or in the
revalence of smoking, diabetes, or hypertension in cases
ersus noncases.
p-PLA2 values and associations with other risk factors.
edian Lp-PLA2 levels were similar in participants who
ere older than 70 compared with those who were younger
nd did not differ by gender, diabetes, or smoking status
Table 2). Lipoprotein-associated phospholipase A2 levels
ere significantly lower in participants who drank alcohol
aily compared with less frequent drinkers. Lipoprotein-
ssociated phospholipase A2 levels positively correlated (all
 0.05) with total cholesterol (r 0.29), LDL cholesterol
r  0.37), and triglycerides (r  0.25) and negatively
orrelated with HDL cholesterol (r  0.27) (Table 3).
eak, but significant, positive associations were also ob-
erved between Lp-PLA2 and systolic blood pressure (r 
.08), CRP (r  0.10), and BMI (r  0.11) (Table 3).
ipoprotein-associated phospholipase A2 levels did not
iffer by use of aspirin or beta-blockers (data not shown).
rediction of incident CHD. In an age- and gender-
djusted Cox proportional hazards regression model, par-
icipants with Lp-PLA2 levels in the second, third, and
ourth quartiles had 66%, 80%, and 89% increased risk of
ncident CHD compared with those in the lowest quartile
all p  0.05) (Table 4, Model 1). Results remained uignificant after further adjustment for cardiovascular risk
actors (Model 2); only fasting plasma glucose levels and
ystolic blood pressure remained in the final model (Model
). When analysis was limited to those who had CRP
easurements, results were significant for the third and
ourth quartiles of Lp-PLA2 (Model 4), with risk estimates
imilar to those for the entire study group. Additional
djustment for CRP levels had minimal effect on the
p-PLA2-incident CHD association (Model 5). Results
ere also similar when those with LDL levels above the
edian were compared with those with LDL levels below
he median (data not shown). There was no interaction of
ender and Lp-PLA2 in any of these models. Figure 1
hows graded age-adjusted CHD event-free survival by
p-PLA2 tertile (p  0.01).
Receiver-operating characteristic curves were constructed
o evaluate the incremental benefit of Lp-PLA2 in predict-
ng incident CHD. Although the addition of CRP to a
odel including age, gender, hypertension, diabetes, smok-
ng, and exercise did not change the area under the curve
0.595 [95% CI 0.549 to 0.640] vs. 0.595 [95% CI 0.550 to
.641], p  0.93), the further addition of Lp-PLA2
ignificantly increased the area under the curve to 0.617
95% CI 0.572 to 0.662) (p  0.04) (Table 5).
The overall findings remained the same when the defi-
ition of incident CHD excluded angina or was limited to
yocardial infarction or revascularization or myocardial
nfarction alone.
iscussion
n the present study of older community-dwelling individ-
edian Lp-PLA2 Levels by Baseline Characteristics
Table 2 Median Lp-PLA2 Levels by Baseline Characteristics
Variable n
Lp-PLA2
(ng/ml) IQR p Value
Gender
Male 577 496 234 0.12
Female 500 477 202
Age, yrs
70 471 478 223 0.15
70 606 496 209
Diabetes
Diabetic patients 144 514 235 0.14
Nondiabetic patients 933 487 216
Smoking
Current smokers 136 510 246 0.23
Nonsmokers 939 487 214
Exercise
Exercise 3 per week 875 485 215 0.086
Exercise 3 per week 202 517 227
Alcohol
Daily alcohol drinkers 477 476 216 0.048
Less than daily drinkers 599 498 216
QR  interquartile range; Lp-PLA2  lipoprotein-associated phospholipase A2.als, Lp-PLA2 levels were significantly higher in those who
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iations between Lp-PLA2 and LDL, HDL, total choles-
erol, and triglycerides were especially strong, and the
agnitude of the correlations was in good agreement with
revious studies (7,19). Despite these associations, Lp-
LA2 remained a strong and independent predictor of fatal
nd nonfatal CHD events, over and above these and other
raditional risk factors. Thus, Lp-PLA2 added information
o lipid and lipoprotein prediction of future CHD and may
dentify subpopulations at risk for CHD who would not be
dentified otherwise.
A similar independent association of Lp-PLA2 with CHD
isk was reported in the younger participants from the
OSCOPS (5) and ARIC (7,19) studies and in a nested
ase-control study from the Rotterdam study (9). We now
onfirm these results for the first time in a cohort of apparently
orrelation Betweenp-PLA2 a d O h r Risk Factors
Table 3 Correlation BetweenLp-PLA2 and Other Risk Factors
Risk Factor Spearman Rho p Value
Age 0.07 0.018
BMI 0.11 0.001
Systolic BP 0.08 0.010
Diastolic BP 0.01 0.070
Total cholesterol 0.29 0.001
HDL 0.27 0.001
LDL 0.37 0.001
Triglycerides 0.25 0.001
Fasting plasma glucose 0.06 0.054
CRP 0.10 0.003
bbreviations as in Table 1.
Rs (95% CIs) for Incident CHDy Lp-PLA2 Quartile*
Table 4 HRs (95% CIs) for Incident CHDby Lp-PLA2 Quartile*
Lp-PLA2 Quartiles
2nd Quartile 3rd Quartile 4th Quartile
(409.9–488.4 ng/ml) (488.5–625.2 ng/ml) (>625.2 ng/ml)
Model 1 1.66 (1.09–2.54) 1.80 (1.19–2.72) 1.89 (1.26–2.86)
[269] [270] [269]y
CHD  coronary heart disease; CI  confidence interval; HR  hazard ratio; ln  natural
ogarithm; Lp-PLA2  lipoprotein-associated phospholipase A2.
PtI
*
aealthy older men and women followed for a longer period of
ime. In agreement with the ARIC and Rotterdam studies
7,9,19), the adjusted risk of incident CHD was significantly
levated beginning in the second quartile of Lp-PLA2, sug-
esting that, as in middle-aged adults, even minimally elevated
p-PLA2 values are associated with an increased risk of
eveloping CHD in older adults.
The addition of CRP to the fully adjusted model did not
iminish the predictive capability of Lp-PLA2, evidence that
he 2 markers are not codependent. This is in agreement with
revious studies in which Lp-PLA2 maintained significance in
odels adjusted for CRP and all traditional factors in
OSCOPS (relative risk per 1 standard deviation  1.18,
5% CI 1.05 to 1.33) (5) and ARIC (HR of highest tertile
n the LDL 130 mg/dl population  2.08, 95% CI 1.20
o 3.62) (7). Similar results were also seen for the 2 highest
uartiles of Lp-PLA2 in the Rotterdam study CHD anal-
Figure 1 Age-Adjusted Event-Free Survival by Lp-PLA2 Tertile
Age-adjusted survival free of fatal or nonfatal myocardial infarction, coronary
revascularization, or angina, by lipoprotein-associated phospholipase A2 (Lp-
PLA2) tertile (low 108.1 to 434.4 ng/ml; medium 434.4 to 574.2 ng/ml; high
574.3 to 3,126.8 ng/ml). CHD  coronary heart disease.sis (9).Model 2 1.54 (1.01–2.37) 1.71 (1.12–2.61) 1.61 (1.03–2.51)
[269] [270] [269]
Model 3 1.59 (1.04–2.44) 1.83 (1.21–2.77) 1.81 (1.20–2.73)
[269] [270] [269]
Model 4 1.41 (0.87–2.26) 1.93 (1.22–3.07) 1.75 (1.10–2.77)
[211] [198] [199]
Model 5 1.43 (0.89–2.31) 1.96 (1.23–3.10) 1.75 (1.10–2.78)
[211] [198] [199]
Lowest quartile (409.9 ng/ml) is reference. The number in brackets is the n for each quartile.
uartile cutpoints were calculated based on the sample of 1,077. The n for Q1 is [269] for Models
, 2, and 3 and [209] for Models 4 and 5. Model 1 (n 1,077): adjusted for age and gender; Model
(n  1,077): adjusted for age, gender, fasting plasma glucose, systolic blood pressure,
ypertension, diabetes, low-density lipoprotein, lnhigh-density lipoprotein, and lntriglycerides;
odel 3 (n  1,077): adjusted for age, gender, fasting plasma glucose, systolic blood pressure;
odel 4 (n 815): Model 3, but includes only those subjects who had C-reactive protein measured
C-reactive protein not in the model); Model 5 (n  815): Model 4  C-reactive protein.redictive Accuracy of Various Multivariate Modelso Pred ct In ident CHD s Meas red by anncrease in the AUC
Table 5
Predictive Accuracy of Various Multivariate Models
to Predict Incident CHD as Measured by an
Increase in the AUC
Model Adjusted for AUC (95% CI) p Value*
1. Age, gender, hypertension, diabetes,
smoking, exercise
0.595 (0.549–0.640)
2. Above covariates plus CRP 0.595 (0.550–0.641) 0.93
3. Above covariates plus CRP and
Lp-PLA2
0.617 (0.572–0.662) 0.037
p values are for comparisons between 2 consecutive models.
AUC  area under the receiver-operating characteristic curve; CRP  C-reactive protein; other
bbreviations as in Table 4.
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Lp-PLA2 Predicts Incident CHD in Older Adults March 4, 2008:913–9One difference of note is the higher distribution of Lp-
LA2 values in the present study compared with that seen in
revious studies. Mean values of Lp-PLA2 in young adults in
he CARDIA (Coronary Artery Risk Development in Young
dults) study were 296 ng/ml and 267 ng/ml in cases and
ontrol subjects, respectively (20). The middle-aged population
valuated in the ARIC study reported Lp-PLA2 mean values
f 404 ng/ml and 373 ng/ml in cases and control subjects. The
igher values observed in the present study (538 ng/ml for
ases, 494 ng/ml for noncases) may reflect the higher risk in an
lder population, an effect of the decade-long storage of
amples, or may result from other as yet undetermined factors.
lthough we found no difference in Lp-PLA2 values in
articipants older or younger than the median age of 70 years,
p-PLA2 values were significantly higher in subjects 55
ears of age compared with those seen in subjects age 55
ears, lending credence to an age-associated increment in
p-PLA2 at midlife. Although the absolute Lp-PLA2 values
n this study are higher than in previous studies, the correla-
ions between Lp-PLA2 levels and other measures such as
DL and HDL are almost identical to those seen in prior
tudies (6,7,9), supporting the utility if not the optimal cut-
oint for our values.
As a corollary to the observed higher Lp-PLA2 levels in this
lder population, it is likely that nearly all subjects had some
egree of cardiovascular disease pathology since atherosclerotic
urden increases with age. Thus, HRs for cases versus noncases
ight be somewhat lower than in a population where the
oncases have a lower atherosclerotic burden. However, our
bserved HR for incident CHD of 1.6 for the highest versus
owest quartile in the present study is only slightly lower than
he reported HR of approximately 1.8 from WOSCOPS
though quintiles were used there).
One advantage of our study is that the cohort was recruited
n the 1970s. At the time samples were drawn, available
harmacotherapies were limited, and only 5 participants were
aking lipid-lowering medications. Also during this time pe-
iod, few were taking aspirin regularly for cardiovascular
revention. If our subjects’ use of statins, angiotensin-
onverting enzyme inhibitors, and anti-inflammatory medica-
ions was more in line with the present higher levels of use, the
erceived utility of Lp-PLA2 might have been altered. It is
nknown whether the modern pharmacotherapies would at-
enuate, accentuate, or have no effect on the predictive capa-
ility of Lp-PLA2. Additional studies are required to identify
nd characterize the magnitude of any such alterations.
onclusions
n summary, in a cohort of community-dwelling older adults
ollowed for an average of 16 years, measurement of Lp-PLA2
ass demonstrated strong predictive capability for subsequent
HD events. This predictive capability was independent of
raditional risk factors of CHD and in accord with previous
ndings. The present study extends the previous findings intohe older population and represents a potential clinical appli-
ation of Lp-PLA2 measurements in identification of individ-
als at risk for CHD who would not otherwise be identified by
raditional measures.
eprint requests and correspondence: Dr. Lori B. Daniels, Mail
ode 0986, 9350 Campus Point Drive, Suite 1D, La Jolla,
alifornia 92037. E-mail: lbdaniels@ucsd.edu.
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